STK16
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| serine/threonine kinase 16 | MIM:604719 | Ensembl:ENSG00000115661 | HGNC:HGNC:11394 | PA36202 | 2q35 |
GO terms in STK16
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IEA | GO:0001077 | transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding |
| MF | IEA | GO:0004715 | non-membrane spanning protein tyrosine kinase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| CC | IEA | GO:0005798 | Golgi-associated vesicle |
| CC | IDA | GO:0005829 | cytosol |
| CC | IEA | GO:0016020 | membrane |
| CC | IEA | GO:0048471 | perinuclear region of cytoplasm |
| BP | IEA | GO:0006366 | transcription by RNA polymerase II |
| BP | IEA | GO:0018108 | peptidyl-tyrosine phosphorylation |
| BP | IEA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IDA | GO:0046777 | protein autophosphorylation |
| BP | IBA | GO:0071560 | cellular response to transforming growth factor beta stimulus |
Gene expression in normal tissue: STK16
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in STK16
| Database | Pathway ID | Pathway Des. |
|---|
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD137 | Indisulam | 3 |
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD870 | BRD63610 | 1 |
| iGMDRD872 | BRD7137 | 3 |
| iGMDRD188 | Piperlongumine | 3 |
| iGMDRD398 | Sepantronium | 3 |
| iGMDRD147 | Prima-1 | 3 |
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD268 | Cerulenin | 3 |
| iGMDRD126 | Tipifarnib | 3 |
| iGMDRD772 | BRD4770 | 3 |
| iGMDRD512 | nutlin 3 | 3 |
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD150 | RITA | 3 |
| iGMDRD781 | Sirolimus | 3 |
| iGMDRD394 | BX-795 | 1 |
| iGMDRD634 | SCHEMBL2608041 | 1 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in STK16

